Thomas J. Galletta, MD
- Member, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
About
Biography
As a physician I am constantly reminding myself that each interaction I have with a patient and family is an opportunity for them to have a positive experience. In treating children and young adults with cancer, this opportunity is even more important. I aim to care for each patient and caregiver in the way I would want my own family to be cared for. From choosing specialized evidence-based treatment plans, to providing my full attention at the bedside or clinic visit, I want each patient and caregiver to recognize that I am fully dedicated to their care.
I am a pediatric oncologist and specialize in the care of children and young adults with leukemias and lymphomas. While the outcomes for these diseases have improved dramatically over the past decades, the likelihood of cure for patients with certain relapsed and/or refractory cases remains poor.
Additionally, complications of treatment can impact survival and quality of life, both during active therapy and for years after. My research focuses on using novel therapies, including chemotherapy, cellular therapy, and immunotherapy, to treat relapsed/refractory leukemias. I am also interested in how these advancements can treat cancer with less toxic immediate and long-term side effects.”
Undergraduate: University of Pittsburgh, Pittsburgh, PA.
MD: Northeast Ohio Medical University, Rootstown, OH.
Residency: Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: American Board of Pediatrics, 2020.
Interests
Pediatric oncology; leukemia; lymphoma; cellular therapy; immunotherapy
Services and Specialties
Cancer Blood Disease Institute
Interests
Cellular and immune therapies for the treatment of relapsed/refractory acute leukemias and viral infections; mechanisms of cancer predisposition and oxidative stress in Fanconi anemia; non-hematologic complications of bone marrow failure syndromes
Research Areas
Oncology
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Transplantation and cellular therapy. 2023; 29:305-310.
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.
356 Children Under 2 Years Old Treated with Ruxolitinib for Acute and Chronic Graft-Versus-Host-Disease Demonstrate Variable Pharmacokinetics. Transplantation and cellular therapy. 2023; 29:s271-s272.
Coronavirus disease 2019 and vaccination in patients with Shwachman-Diamond syndrome. Pediatric Blood and Cancer. 2022; 69:e29647.
477 Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant. Transplantation and cellular therapy. 2022; 28:s374-s375.
TRPM7 is a crucial regulator of pancreatic endocrine development and high-fat-diet-induced β-cell proliferation. Development (Cambridge). 2021; 148:dev194928.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
